Antibiotics

>

Latest News

 Ceftobiprole Launches Commercially in US
Ceftobiprole Launches Commercially in US

May 20th 2025

Innoviva Specialty Therapeutics’ antibiotic is the first and only FDA-approved cephalosporin indicated to treat Staphylococcus aureus bacteremia, including right-sided endocarditis, caused by the methicillin-resistant Staphylococcus aureus.

With Its Global Bacterial Meningitis Guidelines, WHO Aims to Speed Up Diagnosis, Treatment
With Its Global Bacterial Meningitis Guidelines, WHO Aims to Speed Up Diagnosis, Treatment

May 19th 2025

Greater Incidence of Antimicrobial-Resistant Infections in Outpatients With Cancer
Greater Incidence of Antimicrobial-Resistant Infections in Outpatients With Cancer

May 13th 2025

Wiki-What? Navigating WikiGuidelines and Leveraging Their Advantages
Wiki-What? Navigating WikiGuidelines and Leveraging Their Advantages

May 7th 2025

Model Evidences Wide Treatment Gap for Carbapenem-Resistant Gram-Negative Infections
Model Evidences Wide Treatment Gap for Carbapenem-Resistant Gram-Negative Infections

May 7th 2025

Video Series
Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.